Guggenheim Reiterates Buy on Endo Int'l (ENDP) Following Updated Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Endo Completes Acquisition of Par Pharmaceutical and Provides Financial Guidance
September 28, 2015 6:30 AM EDT-Â Â Par Acquisition Enhances Endo's Position as a Leading Global Specialty Pharmaceutical Company with One of Industry's Fastest Growing Generics Businesses and Establishes Powerful Platform for Future Growth and Strategic M&A
-Â Â Combined U.S. Generics Business Unit to be Named Par Pharmaceutical, an Endo International Company
-Â Â Updated 2015 Full Year Financial Guidance to $3.22 to $3.27 Billion in Revenues; Endo Maintains Upper End of 2015 Adjusted Diluted EPS from Continuing Operations Guidance of $4.50 to $4.60
-Â 2016 Adjusted Diluted EPS from Continuing Operations Expected to be in the Range of... More
Endo Announces Termination Of HSR Act Waiting Period In Connection With Its Proposed Acquisition Of Par Pharmaceutical
September 25, 2015 6:00 AM EDTDUBLIN, Sept. 25, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced that on September 24, 2015, it received notice of termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, from the U.S. Federal Trade Commission in connection with Endo's previously... More
